154 related articles for article (PubMed ID: 37970435)
1. Expression of Galectin-9-related immune checkpoint receptors in B-cell acute lymphoblastic leukemia.
Akbar A; Asgarian-Omran H; Valadan R; Dindarloo MM; Najafi A; Kahrizi A; Poursheikhani A; Karami H; Naderi M; Sabeti S; Tehrani M
Iran J Basic Med Sci; 2023; 26(12):1468-1474. PubMed ID: 37970435
[TBL] [Abstract][Full Text] [Related]
2. LAG-3, TIM-3 and VISTA Expression on Tumor-Infiltrating Lymphocytes in Oropharyngeal Squamous Cell Carcinoma-Potential Biomarkers for Targeted Therapy Concepts.
Wuerdemann N; Pütz K; Eckel H; Jain R; Wittekindt C; Huebbers CU; Sharma SJ; Langer C; Gattenlöhner S; Büttner R; Speel EJ; Suchan M; Wagner S; Quaas A; Klussmann JP
Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33396515
[TBL] [Abstract][Full Text] [Related]
3. Expression of immune checkpoint molecules of T cell immunoglobulin and mucin protein 3/galectin-9 for NK cell suppression in human gastrointestinal stromal tumors.
Komita H; Koido S; Hayashi K; Kan S; Ito M; Kamata Y; Suzuki M; Homma S
Oncol Rep; 2015 Oct; 34(4):2099-105. PubMed ID: 26239720
[TBL] [Abstract][Full Text] [Related]
4. Expression of Tim-3/Galectin-9 pathway and CD8+T cells and related factors in patients with cystic echinococcosis.
Zhao H; Ma Y; Tian F; Li B; Xiao N; Mo X; Aibibula M; Min H; Cai X; Zhang T; Ma X
Exp Parasitol; 2023 Nov; 254():108623. PubMed ID: 37793539
[TBL] [Abstract][Full Text] [Related]
5. Different expression patterns of VISTA concurrent with PD-1, Tim-3, and TIGIT on T cell subsets in peripheral blood and bone marrow from patients with multiple myeloma.
Huang S; Zhao Y; Liao P; Wang J; Li Z; Tan J; Zha X; Chen S; Li Y; Zhong L
Front Oncol; 2022; 12():1014904. PubMed ID: 36439426
[TBL] [Abstract][Full Text] [Related]
6. The effect of Curcumin on multi-level immune checkpoint blockade and T cell dysfunction in head and neck cancer.
Liu L; Lim MA; Jung SN; Oh C; Won HR; Jin YL; Piao Y; Kim HJ; Chang JW; Koo BS
Phytomedicine; 2021 Nov; 92():153758. PubMed ID: 34592487
[TBL] [Abstract][Full Text] [Related]
7. Functional expression of Tim-3 on blasts and clinical impact of its ligand galectin-9 in myelodysplastic syndromes.
Asayama T; Tamura H; Ishibashi M; Kuribayashi-Hamada Y; Onodera-Kondo A; Okuyama N; Yamada A; Shimizu M; Moriya K; Takahashi H; Inokuchi K
Oncotarget; 2017 Oct; 8(51):88904-88917. PubMed ID: 29179486
[TBL] [Abstract][Full Text] [Related]
8. Expression of the checkpoint receptors LAG-3, TIM-3 and VISTA in peripheral T cell lymphomas.
Murga-Zamalloa CA; Brown NA; Wilcox RA
J Clin Pathol; 2020 Apr; 73(4):197-203. PubMed ID: 31672704
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of the expression levels of T-cell immunoglobulin mucin-3 and its ligand galectin-9 for relapse-free survival in triple-negative breast cancer.
Yoshikawa K; Ishida M; Yanai H; Tsuta K; Sekimoto M; Sugie T
Oncol Lett; 2022 Jun; 23(6):197. PubMed ID: 35572493
[TBL] [Abstract][Full Text] [Related]
10. Tim-3/galectin-9 signaling pathway mediates T-cell dysfunction and predicts poor prognosis in patients with hepatitis B virus-associated hepatocellular carcinoma.
Li H; Wu K; Tao K; Chen L; Zheng Q; Lu X; Liu J; Shi L; Liu C; Wang G; Zou W
Hepatology; 2012 Oct; 56(4):1342-51. PubMed ID: 22505239
[TBL] [Abstract][Full Text] [Related]
11. TIM-3 does not act as a receptor for galectin-9.
Leitner J; Rieger A; Pickl WF; Zlabinger G; Grabmeier-Pfistershammer K; Steinberger P
PLoS Pathog; 2013 Mar; 9(3):e1003253. PubMed ID: 23555261
[TBL] [Abstract][Full Text] [Related]
12. The presence of TIM-3 positive cells in WHO grade III and IV astrocytic gliomas correlates with isocitrate dehydrogenase mutation status.
Sørensen MD; Nielsen O; Reifenberger G; Kristensen BW
Brain Pathol; 2021 May; 31(3):e12921. PubMed ID: 33244787
[TBL] [Abstract][Full Text] [Related]
13. Upregulation of the Tim-3/galectin-9 pathway of T cell exhaustion in chronic hepatitis B virus infection.
Nebbia G; Peppa D; Schurich A; Khanna P; Singh HD; Cheng Y; Rosenberg W; Dusheiko G; Gilson R; ChinAleong J; Kennedy P; Maini MK
PLoS One; 2012; 7(10):e47648. PubMed ID: 23112829
[TBL] [Abstract][Full Text] [Related]
14. [Expression and Significance of PD-1, TIM-3 and VISTA on T Cell of Acute Myeloid Leukemia Patients].
Ge MJ; Xu KL; Xu T; Tang YN; Li ZY; Yan ZL; Sun HY; Cheng H; Zhu F; Sang W; Huang YH; Qiu TT; Li DP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Jun; 28(3):748-752. PubMed ID: 32552931
[TBL] [Abstract][Full Text] [Related]
15. Molecular and immune correlates of TIM-3 (HAVCR2) and galectin 9 (LGALS9) mRNA expression and DNA methylation in melanoma.
Holderried TAW; de Vos L; Bawden EG; Vogt TJ; Dietrich J; Zarbl R; Bootz F; Kristiansen G; Brossart P; Landsberg J; Dietrich D
Clin Epigenetics; 2019 Nov; 11(1):161. PubMed ID: 31747929
[TBL] [Abstract][Full Text] [Related]
16. Oncolytic adenovirus decreases the proportion of TIM-3
Liikanen I; Basnet S; Quixabeira DCA; Taipale K; Hemminki O; Oksanen M; Kankainen M; Juhila J; Kanerva A; Joensuu T; Tähtinen S; Hemminki A
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35193929
[TBL] [Abstract][Full Text] [Related]
17. TIM-3 in Leukemia; Immune Response and Beyond.
Rezaei M; Tan J; Zeng C; Li Y; Ganjalikhani-Hakemi M
Front Oncol; 2021; 11():753677. PubMed ID: 34660319
[TBL] [Abstract][Full Text] [Related]
18. Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia.
Zhou Q; Munger ME; Veenstra RG; Weigel BJ; Hirashima M; Munn DH; Murphy WJ; Azuma M; Anderson AC; Kuchroo VK; Blazar BR
Blood; 2011 Apr; 117(17):4501-10. PubMed ID: 21385853
[TBL] [Abstract][Full Text] [Related]
19. Increased TOX expression concurrent with PD-1, Tim-3, and CD244 expression in T cells from patients with acute myeloid leukemia.
Huang S; Liang C; Zhao Y; Deng T; Tan J; Zha X; Li Y; Chen S
Cytometry B Clin Cytom; 2022 Mar; 102(2):143-152. PubMed ID: 34913594
[TBL] [Abstract][Full Text] [Related]
20. Combined Immune Checkpoint Blockade Enhances Antiviral Immunity against Bovine Leukemia Virus.
Nakamura H; Konnai S; Okagawa T; Maekawa N; Sajiki Y; Watari K; Kamitani K; Saito M; Kato Y; Suzuki Y; Murata S; Ohashi K
J Virol; 2023 Jan; 97(1):e0143022. PubMed ID: 36598199
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
